Upstream Bio

Upstream Bio is an American immunotherapy drug developer focused on the field of drug research and development, primarily engaged in drug R&D operations, dedicated to the development of drugs for treating inflammatory diseases. Upstream Bio's main program is a clinical-stage monoclonal antibody that inhibits the TSLP receptor. TSLP is a validated target located upstream of multiple signaling cascades, which influence various immune cells critical to both common and rare diseases.